Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.63 |
| ▸ | JAK1 | P23458 | 5/20 | 0.63 |
| ▸ | TYK2 | P29597 | 5/20 | 0.63 |
| ▸ | JAK3 | P52333 | 5/20 | 0.63 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18398443 | 0.91 | JAK2 (0.61) | JAK2JAK1TYK2JAK3CTSS | |
| SCHEMBL18398389 | 0.91 | JAK2 (0.61) | JAK2JAK1TYK2JAK3CTSS | |
| SCHEMBL18398237 | 0.91 | JAK2 (0.60) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL18409359 | 0.90 | JAK2 (0.58) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL18398346 | 0.89 | JAK2 (0.59) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL18409163 | 0.89 | TYK2 (0.75) | JAK2JAK1TYK2JAK3EGLN2 | |
| SCHEMBL18409279 | 0.88 | JAK2 (0.58) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL18398558 | 0.88 | JAK2 (0.58) | JAK2JAK1TYK2JAK3EGLN2 | |
| SCHEMBL18409127 | 0.88 | JAK2 (0.60) | JAK2JAK1TYK2JAK3EGLN2 | |
| SCHEMBL18398513 | 0.88 | TYK2 (0.62) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |